The Pathology and Tissue Resources Core will provide routine and innovative tissue resources and materials essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 3,000 tumors and 300 lung cancer cell lines have been banked, and over 50,000 aliqouts of tumor or cell line pellets, RNA or DNA or paraffin sections have been distributed to investigators.
Our Aim 1 is to collect, process, store, catalog and distribute tissues, cell lines and blood specimens, both malignant and nonmalignant, and relevant clinico-pathologic and molecular data, as requested by the various component projects of the SPORE program.
Aim 2 is to develop and utilize innovative and routine tissue and cell line resources that will aid in the successful completion of the SPORE program aims. These include development of new tumor cell line resources to complement recent genome wide mutation data on lung cancer oncogenotypes.
Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This will involve developing molecular assays that eventually can be deployed as CLIA certified lab tests to facilitate the planned translational science clinical trials in most of the SPORE projects. This Core will play a crucial role on promoting collaboration among our own SPORE investigators, investigators at other Lung Cancer SPORE sites, and investigators at our own and other institutions including other peer-reviewed projects funded by NCI/NIH and other agencies. All of our SPORE projects will utilize Core B materials and services. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal.
All of the proposed lung cancer translational research is critically dependent on tumor and cell line resources provided by this Core. These include both the detailed clinical, and genome wide molecular annotation of many of the tumor and cell line specimens. These resources will also greatly facilitate inter-SPORE and inter-institutional collaborations.
|Goodwin, Justin; Neugent, Michael L; Lee, Shin Yup et al. (2017) The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. Nat Commun 8:15503|
|Cao, Xiaobo; Zhao, Yang; Wang, Jing et al. (2017) TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC). Oncotarget 8:107621-107629|
|Zhou, Fei; Wang, Yanru; Liu, Hongliang et al. (2017) Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs. Mol Carcinog 56:1227-1238|
|Tagal, Vural; Wei, Shuguang; Zhang, Wei et al. (2017) SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun 8:14098|
|Jafri, Mohammad Alam; Al-Qahtani, Mohammed Hussein; Shay, Jerry William (2017) Role of miRNAs in human cancer metastasis: Implications for therapeutic intervention. Semin Cancer Biol 44:117-131|
|Cardnell, Robert J; Li, Lerong; Sen, Triparna et al. (2017) Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget 8:73419-73432|
|Faubert, Brandon; Li, Kevin Y; Cai, Ling et al. (2017) Lactate Metabolism in Human Lung Tumors. Cell 171:358-371.e9|
|Rabellino, Andrea; Andreani, Cristina; Scaglioni, Pier Paolo (2017) The Role of PIAS SUMO E3-Ligases in Cancer. Cancer Res 77:1542-1547|
|Fu, Rong; Wang, Pei; Ma, Weiping et al. (2017) A statistical method for detecting differentially expressed SNVs based on next-generation RNA-seq data. Biometrics 73:42-51|
|Quek, Kelly; Li, Jun; Estecio, Marcos et al. (2017) DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget 8:21994-22002|
Showing the most recent 10 out of 1004 publications